Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13873518 | 0.94 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2GAAMAPTHTT | |
| SCHEMBL13873703 | 0.87 | MMP1 (0.56) | ALDH1A1SMN1; SMN2MAPTLMNARAB9A | |
| SCHEMBL13873506 | 0.84 | HTR2A (0.62) | ALDH1A1GAAMEN1KMT2ATSHR | |
| SCHEMBL13873717 | 0.82 | HTR2A (0.54) | ALDH1A1SMN1; SMN2GAAMEN1KMT2A | |
| SCHEMBL13873502 | 0.82 | PKM (0.50) | RAB9AMEN1KMT2A | |
| SCHEMBL13873723 | 0.81 | MMP1 (0.59) | ALDH1A1SMN1; SMN2MAPTLMNARAB9A | |
| SCHEMBL13873510 | 0.81 | CA1 (0.51) | ALDH1A1SMN1; SMN2MAPTLMNARAB9A | |
| SCHEMBL13873511 | 0.79 | HTR2A (0.53) | ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL13873520 | 0.78 | HTR2A (0.56) | ALDH1A1SMN1; SMN2GAARAB9AMEN1 | |
| SCHEMBL5462633 | 0.78 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2MAPTLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| WO-2007106705-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHODS OF USING SAME | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | EPHX1, EPHX2, NCEH1 | ALDH1A1 385/4885SMN1; SMN2 4277/4885GAA 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.